Table 2.

Performance of gene signatures in a PDX model and triple-negative breast cancer patients

	Response to Olaparib in PDX (n=7)						TCGA (n=82)
Gene signatures	Acc	Sens	Spec	PPV	NPV	Positive test	Positive Test
Combined PARP inhibitor	0.86	0.75	1.00	1.00	0.75	0.43	0.45
Olaparib (Bajrami et al.) (24)	0.71	0.50	1.00	0.50	0.60	0.29	0.49
Talazoparib (Shen et al.) (25)	0.71	0.75	0.67	0.75	0.67	0.43	0.41
HRD Deficiency (Peng et al.) (28)	0.71	0.50	1.00	0.50	0.60	0.29	0.29
Olaparib (Daemen et al.) (20)	0.57	0.25	1.00	1.00	0.50	0.14	0.48
BRCAness (Konstantinopoulos et al.) (26)	0.57	0.75	0.33	0.60	0.50	0.71	0.78
BRCA2MUT (Larsen et al.) (27)	0.43	0.50	0.33	0.50	0.33	0.57	0.68
BRCA1MUT (Larsen et al.) (27)	0.29	0.50	0.00	0.40	0.00	0.71	0.51

Abbreviations: Acc, overall accuracy; Sens, sensitivity; Spec, specificity; PPV, positive predictive value, NPV, negative predictive value.